President-elect Donald Trump‘s transition team is planning to eliminate a $7,500 electric vehicle tax credit that helps ...

The therapeutic candidate is under development for the treatment of ovarian cancer. It comprises of induced pluripotent stem (iPS) cell derived natural killer (iNK) cell.

TCA-101 is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Solid Tumor.

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Even before Trump enters the White House, the planet is showing worrying vital signs with scientists virtually certain 2024 ...